Poolbeg Pharma Ltd. (POLB) AI Stock Analysis

• Market Cap: £30.33M
• Dividend Yield: N/A
• Average Volume (3M): 1.12M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 697,200,000
• 10 Day Avg. Volume: 836,211
• 30 Day Avg. Volume: 1,116,415
• PEG Ratio: 0.06
• Price to Book (P/B): 3.82
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: 4.00p ▲(12.68% Upside)

The score is held back primarily by weak financial performance (no revenue, widening losses, and continued cash burn), partially offset by a debt-free balance sheet. Technicals are modestly supportive with neutral momentum, while valuation remains constrained by losses and the absence of a dividend.

Poolbeg Pharma Ltd. Business Overview & Revenue Model

Company Description

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class intranasally administered RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Poolbeg Pharma Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-127.00K	-114.00K	-26.00K	-26.00K	-18.00K
EBITDA	-5.69M	-6.00M	-4.66M	-4.75M	-2.32M
Net Income	-5.71M	-5.79M	-3.93M	-4.69M	-2.34M
Balance Sheet
Total Assets	12.36M	10.25M	15.43M	19.29M	23.02M
Cash, Cash Equivalents and Short-Term Investments	9.96M	7.82M	12.17M	16.19M	20.95M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	429.00K	974.00K	986.00K	966.00K	438.00K
Stockholders Equity	11.93M	9.27M	14.44M	18.32M	22.58M
Cash Flow
Free Cash Flow	-4.73M	-4.78M	-4.02M	-4.96M	-2.23M
Operating Cash Flow	-4.73M	-4.65M	-3.85M	-4.37M	-2.15M
Investing Cash Flow	143.00K	299.00K	359.00K	-388.00K	-81.00K
Financing Cash Flow	4.49M	0.00	0.00	0.00	23.18M

Poolbeg Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HVO	73 Outperform	£42.59M	7.95	―	2.94%	11.92%	-33.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POLB	49 Neutral	£30.33M	-3.82	-46.84%	―	―	―
SAR	47 Neutral	£27.61M	-5.93	-202.14%	―	―	23.76%
IMM	46 Neutral	£36.70M	-8.20	-259.88%	―	―	―
CIZ	43 Neutral	£6.14M	-5.54	-433.59%	―	―	―
NFX	42 Neutral	£6.12M	-0.67	-153.80%	―	―	-616.67%

Poolbeg Pharma Ltd. Corporate Events

Poolbeg Pharma Anticipates Clinical Breakthroughs Following a Year of Progress in 2025

Poolbeg Pharma reported significant advancements in 2025, culminating in a successful fundraise and strategic preparations for upcoming clinical trials in 2026. Key developments include progress with POLB 001, central to a multi-centre TOPICAL trial addressing CRS in cancer immunotherapy, and an innovative obesity therapy program. Positioned as a leader in cancer immunotherapy solutions and leveraging substantial funding, Poolbeg is preparing for major clinical milestones and partnerships, enhancing its market potential and opportunities in healthcare innovation.

Poolbeg Pharma Leads in Groundbreaking Cancer Immunotherapy Research

Poolbeg Pharma has announced its participation as the lead business partner in the RISE programme, a groundbreaking research initiative into cancer immunotherapy-induced Cytokine Release Syndrome (CRS), led by The University of Manchester and The Christie NHS Foundation Trust. Supported by a £3.4 million grant from the Medical Research Council, the programme will feature the POLB 001 TOPICAL trial and aims to enhance the safety and delivery of advanced cancer immunotherapies. This collaboration, involving partners like Johnson & Johnson, reflects the growing recognition of the need to manage CRS, which is a significant barrier to the broader adoption of these therapies.

Poolbeg Pharma Secures European Patent for POLB 001

Poolbeg Pharma has been granted a European patent for POLB 001, a p38 MAP kinase inhibitor, for treating severe influenza and cancer immunotherapy-induced Cytokine Release Syndrome. This strengthens Poolbeg’s global intellectual property portfolio, enhancing the value and appeal of POLB 001 to potential partners and addressing significant unmet medical needs in healthcare.